LEXARIA BIOSCIENCE CORP (LEXX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$14.15+14.85%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LEXX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 143.6% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| -60.0% |
Growth built into the price is above our model estimate.
The price assumes 203.6 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
LEXX — legal / regulatory event — Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard;…
Dated 2026-08-10
Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing Nasdaq Delisting Notification On August 4, 2026 Lexaria Bioscience Corp. (the “Company”) received a notification (the “Notification”) from the Nasdaq Capital Market (“Nasdaq”) that, due to its failure to regain compliance with Nasdaq Listing Rule 5550(a)(2), being the requirement to maintain a $1.00 minimum bid price, (the “Bid Price Requirement”) within the 180 day compliance period provided und…
Why it matters: FOMC decisions can change how investors feel. This can impact stocks in health care.
Watch forFOMC decision on July 29 indicates a rate hike or hawkish stance.
Also watch forFOMC decision on July 29 indicates a rate cut or dovish stance.
Why it matters: Advancements in the DehydraTECH platform could lead to new partnerships and revenue. The company currently has no revenue, so progress is key.
Supportive ifManagement talks about a new partnership. They also share a big research milestone for DehydraTECH.
Worry ifNo new developments or partnerships are announced in the next quarter.
Why it matters: A drop in revenue growth signals a weakening position in the health care sector. This could affect investor confidence.
Worry ifRevenue growth falls below the sector median growth rate.
Less concerning ifRevenue growth remains above the sector median growth rate.
Why it matters: If healthcare sector growth speeds up, it could help LEXX improve its position. A stronger sector may boost investor confidence.
Supportive ifHealthcare sector revenue growth exceeds 10% over the next quarter.
Worry ifHealthcare sector revenue growth remains below 5% over the next quarter.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$367 on $10,000 · ±3.7% | How much price usually moves either way. |
| Bad day | $914 loss on $10,000 · 9.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,930 loss on $10,000 · 79.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The outcome of the Nasdaq compliance hearing is critical for the company's listing status. A negative outcome could lead to delisting.
Worry ifThe company wins its appeal and stays listed on Nasdaq.
Less concerning ifThe company is removed from Nasdaq after the hearing.
Why it matters: The outcome of the Nasdaq hearing will determine if Lexaria remains listed. This affects investor confidence.
Worry ifLexaria gets a good decision from Nasdaq to stay listed.
Less concerning ifNasdaq confirms the delisting of Lexaria Bioscience Corp.
Why it matters: The reverse stock split aims to meet Nasdaq's $1.00 minimum bid price. A successful outcome could stabilize the stock and attract investors.
Supportive ifThe share price remains above $1.00 for at least two consecutive weeks post-split.
Worry ifThe share price falls below $1.00 within two weeks after the split.